Based on this rationale, several composite indices have been developed using the creatinine-to-cystatin C ratio, such as the Cr/CysC ratio, Sarcopenia Index, and more recently, the pSMI, which may serve as a non-invasive proxy for estimating muscle mass and identifying individuals at risk of sarcopenia (10–14). The gene discussed is CST3; the disease is sarcopenia.